Venetoclax provides a robust targeted-therapy option for the full spectrum of patients with CLL, including those with high-risk del(17p)/mutated-TP53 CLL and those with disease refractory to chemoimmunotherapy. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.